Fidelity International
MYGN icon

Fidelity International’s Myriad Genetics MYGN Stock Holding History

Fidelity International’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-27,773
Closed -$922K – 950
2019
Q1 		$922K Buy
+27,773
New +$845K ﹤0.01% 618

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity International's MYGN Position: Q2 2019 in Review

Fidelity International sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 27,773 shares — an estimated $922K sold.

Fidelity International first reported a position in MYGN in Q1 2019 and held it in 1 quarter. The position peaked at $922K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Fidelity International reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Fidelity International sold 27,773 Myriad Genetics shares in Q2 2019, an estimated $922K.
  • Fidelity International first reported a position in Myriad Genetics in Q1 2019 and held it in 1 quarter.
  • Fidelity International's Myriad Genetics position peaked at $922K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Fidelity International's 13F filing for Q2 2019, filed 13 Aug 2019.